291 related articles for article (PubMed ID: 34082639)
1. Successful retreatment with erlotinib after erlotinib-related interstitial lung disease.
Turk HM; Adli M; Simsek M; Aliyev A; Besiroglu M
Tumori; 2021 Dec; 107(6):NP84-NP86. PubMed ID: 34082639
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
3. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
4. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
5. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
[TBL] [Abstract][Full Text] [Related]
6. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Wu X; Gao G; Ren S; Zhou C
Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
[TBL] [Abstract][Full Text] [Related]
7. Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Ren S; Li Y; Li W; Zhao Z; Jin C; Zhang D
Respiration; 2012; 84(5):431-5. PubMed ID: 22889962
[TBL] [Abstract][Full Text] [Related]
8. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas.
Zhao W; Chen T; Ji C; Xiong L; Li R; Han B; Fang W
Ann Thorac Surg; 2021 Jan; 111(1):290-295. PubMed ID: 32569671
[TBL] [Abstract][Full Text] [Related]
10. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.
Nisaa Zia NU; Khokhar MA; Qamar S; Hanif A; Goraya AW; Awan NU
J Pak Med Assoc; 2019 Nov; 69(11):1605-1609. PubMed ID: 31740864
[TBL] [Abstract][Full Text] [Related]
14. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
15. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Cho SL; Lin WC; Chuang CA; Liao WY; Lai CF
Nephrology (Carlton); 2020 Sep; 25(9):730. PubMed ID: 32364270
[No Abstract] [Full Text] [Related]
16. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Yoneda KY; Shelton DK; Beckett LA; Gandara DR
J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Lai YC; Lin PC; Lai JI; Hsu SY; Kuo LC; Chang SC; Wang WS
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):461-6. PubMed ID: 21726497
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Šťastná N; Jakubíková L; Brat K
Klin Onkol; 2020; 33(3):226-229. PubMed ID: 32683880
[TBL] [Abstract][Full Text] [Related]
19. Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Dallas JL; Jantz MA; Lightsey JL; Sonntag C; Kaye FJ
J Thorac Oncol; 2011 Jun; 6(6):1142-3. PubMed ID: 21623280
[No Abstract] [Full Text] [Related]
20. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
